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Abstract
The existence of an intrinsic biochemical pathway 
enabling specified regulation of gene expression was unheard 
of until the final years of the last decade. The identification 
of ribonucleic acid interference (RNAi) in mammalian cells 
has nowadays become of extreme importance in the field of 
functional genomics and translational medicine. The advent 
of RNAi technology has brought to the scientific research and 
pharmaceutical communities the ability to regulate expression of 
any desired gene in a reproducible manner. Consequently, such 
technology may be utilised in the design of novel therapeutics 
for clinical conditions having dys-regulated gene expression. 
Since most RNAi-based therapies in the drug development 
pipeline of pharmaceutical companies utilise short interfering 
RNA (siRNA), this review will focus on the role of siRNA in 
drug development.
A brief history of RNA interference research
Deciphering the role of genes, including their involvement 
within the intricacies of pathway regulation, has long been 
facilitated by comparison to biological systems where specific 
genes or functions have been deleted. The discovery of 
ribonucleic acid interference (RNAi) in living cells is likely to be 
hailed as one of the most revolutionary milestones in the history 
of molecular biology. The initial evidence for the existence of 
RNAi was through incongruent results obtained from antisense 
studies in plants in the late 1980s.1 This was followed by the 
landmark studies conducted in the 1990s by Professors Andrew 
Fire and Craig Mello2, whereby introduction of double-stranded 
ribonucleic acid (dsRNA) into Caenorhabditis elegans worms 
resulted in impaired expression of specific genes. The role of 
RNAi in plants and lower eukaryotes is focused on preventing 
accumulation of dsRNA derived from intruding viruses, thus 
acting as a primordial antivirus pathway.1 However, scientists 
perceived this mechanism for utilisation in ‘gene silencing’ 
studies, which consist of regulating the expression of a specified 
gene at the post – transcriptomic level. 
The process of transcription, or ribonucleic acid (RNA) 
synthesis, involves the conversion of a specified deoxyribonucleic 
acid (DNA) sequence into RNA via the use of an RNA polymerase 
enzyme. Consequently, the complementary RNA strand formed 
is known as messenger RNA (mRNA), since the transcribed 
RNA sequence contains a genetic ‘message’ from the original 
DNA sequence which is relevant for protein synthesis within the 
cell. Following transcription, the mRNA strand is incorporated 
into cytoplasmic ribosomes which decipher the mRNA template 
sequence as a guide for the creation of a unique polypeptide 
according to the genetic code. This step is known as translation, 
since the mRNA sequence is being translated into an individual 
protein composed of a specific polypeptide sequence based on 
the mRNA strand.
The application of dsRNA for gene silencing presents a risk of 
initiating an interferon-mediated immune response by the host 
organism when exposed to elongated (over 30 base pair length) 
dsRNA due to their potent immunomodulatory properties.3 This 
results in the deleterious consequence of  dsRNA degradation 
in the extra-cellular tissues and blood, thus preventing the 
required effect inside the cell.4 The landmark study by Elbashir 
et al.5 averted this major problem by identifying short interfering 
RNA (siRNA) duplexes which maintained the capacity to induce 
reduction in target gene mRNA expression. In 2006, Professors 
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Fire and Mello both received the Nobel Prize in Medicine for 
their research efforts.
This research field rapidly attracted the attention of major 
pharmaceutical companies, finding the appeal of the RNAi 
pathway as an effective and safe therapeutic measure.6 The main 
potential advantage offered by RNAi technology to the research 
and pharmaceutical community is the capacity to regulate 
expression of any desired gene in a robust manner, thus making 
it valuable as a novel therapy for all clinical conditions based 
on dys-regulated gene expression. Previous studies involved the 
use of antisense oligonucleotides, although the pharmacokinetic 
properties of such compounds is limited, resulting in decreased 
potency.7
Additionally, RNAi also proves to be of enormous help in the 
field of functional genomics, whereby scientists were previously 
dependant on murine ‘knock-out’ models in their investigations, 
which may prove to have flaws.8 Moreover, ‘knock-out’ mice are 
extremely costly and time consuming to develop, together with 
the ethical issues involved with utilising animals in medical 
research.
RNAi research additionally encompasses a spectrum of 
pathway relevant dsRNA-based effector molecules such as 
siRNAs and micro RNAs (miRNAs), involved in evoking the 
desired decrease in target gene expression levels.9,10 It must be 
stated however, that miRNAs form part of an innate intracellular 
pathway designed for control of gene expression11, as opposed 
to siRNAs which are synthetic. Since the many RNAi-based 
therapies in the drug development pipeline of pharmaceutical 
companies utilise siRNA, this review will focus on the role of 
siRNA in drug development.
siRNA mode of action
The siRNA molecule consists of a 21-23 nucleotide dsRNA 
duplex having two-nucleotide  3’ overhangs (Figure 1).12 The two 
strands forming the siRNA molecule are known as the passenger 
and guide strands respectively.13 The passenger strand contains 
the sense sequence for the target mRNA region which requires 
cleavage, whilst the guide strand bears the antisense sequence 
which is complementary to the target mRNA  (Figure 2).12
Once the siRNA duplex successfully enters the target cell 
cytoplasm, by crossing the cell membrane,14 it is recognised 
and attached to an Argonaute protein (AGO2) located within 
the RNA-induced Silencing Complex (RISC).15,16 Consequently, 
only the guide strand is utilised by AGO2 / RISC to seek and 
bind the target complementary mRNA present in the cytoplasm 
by complementarity.16 Finally, the Argonaute protein present in 
the complex cleaves the target mRNA into two segments.16 The 
RISC complex is then free to pursue other target mRNA strands 
displaying the complementary sequence for the siRNA guide 
strand. This pathway is formally defined as Post Transcriptional 
Gene Silencing (PTGS).17
Importance of siRNA in clinical therapeutics
The siRNA-mediated PTGS pathway present in mammalian 
cells18 tantalisingly represents an ideal opportunity for drug 
development scientists to exploit the silencing of specific 
disease-related gene expression. Such genes can be critical in the 
pathogenesis and/or aggravation of a wide spectrum of clinical 
conditions, some of which might prove to be life-threatening 
to the patient. Therefore, the siRNA-based therapy is a highly 
attractive tool in translational medicine research, due to its 
simplicity and robustness in its mode of action and through its 
potential therapeutic effectiveness. 
Pharmaceutical and biotech companies are presently in 
the process of developing novel siRNA-based therapies in their 
product pipeline portfolio (Table 1). Calando Pharmaceuticals 
(USA) are investigating the utilisation of siRNA for controlling 
DNA replication, with the resultant effect of targeting conditions 
such as cancer.19 The siRNA is designed to target the M2 subunit 
of ribonucleotide reductase, which is an enzyme involved in the 
assembly of deoxyribonucleotides for DNA synthesis.19
Quark Pharmaceuticals (USA) is currently developing a 
siRNA treatment against acute renal failure by means of short-
term silencing of the human p53 gene.20 The role of p53 is 
Figure 1: Diagram of a siRNA duplex, illustrating the 
sense passenger (black) and antisense guide (grey) 
strand. The seed region is a unique sequence present 
between, and inclusive of the second and seventh base of 
the guide strand
Figure 2: Simplified representation siRNA mode 
of action in the cell cytoplasm of the cell hosting the 
target gene designated for silencing
Malta Medical Journal    Volume 21   Issue 03   September 2009 15
primarily that of initiating the apoptotic pathways in damaged 
cells following DNA damage or other cellular stress stimuli.21 
Other siRNA therapies undergoing clinical trials are focused 
on Age-related Macular Degeneration (AMD), which is a 
potentially serious condition due to choroidal neovascularization 
(CNV) in the macular region of the eye, leading to severe, 
long-term loss of vision in elderly patients.22 Opko Health Inc. 
(USA) have the siRNA drug candidate bevasiranib which is a 
siRNA duplex complementary to key sequences of the Vascular 
Endothelial Growth Factor (VEGF) gene, and is currently 
undergoing Phase III clinical trials.23 VEGF is an aggravating 
factor for the induction of CNV in the elderly patient22  and is 
thus an ideal target gene for siRNA silencing (or ‘knockdown’). 
Sirna therapeutics Inc (USA) also has a siRNA candidate 
drug which targets Vascular Endothelial Growth Receptor 1 
(VEGFR1).24
Alnylam Pharmaceuticals (USA) has recently initiated Phase 
I clinical trial of the first inhalable siRNA-based therapy, which 
is designed for silencing specific genes in respiratory syncitial 
virus infection in the lungs.25
TransDerm (USA) is another pharmaceutical company which 
has embarked on developing a siRNA-based drug candidate, 
which is capable of silencing the mutant variants of the keratin 
genes K6a, K6b, K16 and K17.26 These mutant keratin genes, once 
expressed at the transcriptomic level, are the causative factors 
for the pathogenesis of pachyonychia congenita.26 
Multiple siRNAs can also be designed and simultaneously 
targeted against a spectrum of oncogenes27  in the case of 
cancer, for the purpose of enhancing the effectiveness of the 
siRNA therapy, by inducing multiple gene knockdown effects 
in the target tissues. The study carried out by Kunze et al. was 
successful in inhibiting the expression of several anti-apoptotic 
genes involved in bladder cancer cells.27  Multiple siRNA 
therapies can also prove to be effective against infective agents 
present in the host mammalian cell, which have the capacity 
to evade individual therapies by mutational escape.28 A typical 
example is the use of several siRNAs directed against specific 
genes aiding the development of the Human Immunodeficiency 
Virus 1 (HIV-1)  at varying stages, thus ensuring that HIV-1 
post-transcriptional protein synthesis is severely impaired and 
there is only a marginal possibility through mutational escape 
by the virus.28 
Gene silencing can also form part of a combination 
therapy with conventional drugs already possessing clinical 
trials approval.29 The study led by Lentini et al. involved the 
administration of the conventional chemotherapeutic agent 
vincristine together with a siRNA duplex targeted against the 
Aurora-A gene, which plays an important role in centrosome 
Figure 4: Illustration of the off target effect of RISC 
binding on siRNA. Step 1; two identical siRNA duplexes 
having a sense (black) and antisense (grey) strand for 
a unique sequence in target gene A, with both duplexes 
present inside target cell cytoplasm. Step 2; RISC 
approaches siRNAs. Step 3; RISC approaches siRNA 
duplex, thus incorporating the antisense or sense strand 
as the siRNA guide strand respectively. Steps 4 and 5 
(Left); siRNA / RISC identify target mRNA sequence 
on gene A and allows for mRNA cleavage as predicted. 
Steps 4 and 5 (Right); due to the sense strand from the 
duplex being incorporated as the guide strand in the 
resultant siRNA / RISC, the latter targets the mRNA 
sequence for an unrelated gene Z which is also present 
in the target cell cytoplasm, brining about its mRNA 
cleavage and consequent off-target effects at the post-
transcriptional level
Figure 3: Some challenges facing siRNA delivery into 
target cells. Recognition by circulating interferon, 
degradation by serum nucleases and difficulty in 
traversing target cell membranes (Diagram reproduced 
by courtesy of Dr. A. Nasti, Federico II University, Naples)
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Table1: List of siRNA based therapeutics currently under development 
Company Target Indication of Development Reference/s
 Gene Treatment Phase Status 
Calando Pharmaceuticals M2 subunit of 
 ribonucleotide reductase Solid Tumour Cancer  I  19
Quark Pharmaceuticals P53 Acute Renal Failure  I  20
Opko Health Inc. Vascular Endothelial  Age-related Macular  III  23
 Growth Factor (VEGF) Degeneration  
Sirna Therapeutics Inc. Vascular Endothelial Age-related Macular  II  24 
 Growth Receptor 1 (VEGFR1) Degeneration
Alnylam Pharmaceuticals Respiratory Syncytial Respiratory Syncytial Virus  II  25
 Virus (RSV) genes
TransDerm Inc. mutant keratin genes Pachyonychia Congenita  I  26
 K6a, K6b, K16 and K17
development and cell cycle progression in human cells.29 The 
study highlighted the synergic effect of combining both siRNA 
and conventional anti-neoplastic therapy on human colon 
cancer cells which were previously rendered resistant to other 
chemotherapeutic agents due to Aurora-A over-expression.29
Challenges awaiting effective 
siRNA therapeutics
Unfortunately, the research and development of siRNA 
‘magic bullets’ is never straightforward and many hurdles 
have to be dealt with before an effective drug candidate 
can be deemed to obtain all the necessary requirements for 
commercialisation.
Major concerns regarding systemic administration of siRNA 
duplexes in sufficient levels to reach target tissues still need to 
be resolved (Figure 3). Once introduced into the bloodstream, 
siRNA effectors are exposed to a multitude of threats during their 
transport to the target tissue, such as the risk of degradation by 
nucleases30  present in the blood and initiation of interferon-
mediated immune responses.3 Additionally, the siRNA duplex 
must have the capacity to be successfully taken up by the target 
tissue cells, which might prove to be problematic due to the 
structural nature of the siRNA duplex.30
One of the biggest obstacles involved in siRNA therapeutics 
research is a threat that the siRNA duplex silences the expression 
of genes which are not being targeted, but which may have 
highly similar signature mRNA sequences, or alternatively the 
sense strand being inadvertently utilised as the guide strand in 
the siRNA/RISC model (Figure 4). Such off-target effects can 
be split into two main problems, the first one being the ability 
of an individual siRNA duplex to induce mRNA degradation of 
non-target genes.31 Secondly, siRNA duplexes might bind to non-
target transcripts having three or four mismatches in sequence 
complementarity and thus affect translation of the off – target 
gene, with a consequent alteration in protein synthesis for the 
specific off – target gene.31 
At present, the siRNA design strategies required to 
minimise off-target effects are quite limited. However, the study 
performed by Jackson et al.32 demonstrated that the seed region 
of the siRNA guide strand sequence (positions 2 to 7) must be 
uniquely complementary to the target gene mRNA sequence for 
minimising off – target effects (Figure 1). Additionally, scientific 
research companies and academic groups involved in siRNA 
research have developed free online applications which allow the 
researcher to design the best siRNA duplex sequences in order 
to knock-down his or her target gene of choice, with minimal 
off – target effects.33,34 The tools apply mathematical algorithms 
which aim to minimise such off - target effects and maximise 
gene knockdown capacity by any one siRNA duplex.
Luckily, the research themes focusing on efficient siRNA 
systemic delivery systems look much more promising (Table 
2). If the siRNA effector is successfully ‘shielded’ during its 
transport inside the bloodstream, the risk of nuclease – mediated 
degradation may be lowered to negligible levels, thus enhancing 
the bioavailability of the intact siRNA therapeutic agent. Studies 
investigating chemical modifications of the siRNA duplex, for 
the purpose of avoiding siRNA systemic recognition by nucleases 
and interferon, have proved to be a successful  strategy.14 
Other delivery systems involve the utilisation of liposomes 
as a means of protecting the siRNA duplex against systemic 
degradation.35,36 Attachment of target tissue specific monoclonal 
antibodies to liposome delivery systems enables the siRNA 
effector to home onto the therapeutic site with enhanced success 
and reducing effects on other tissues.37 However, monoclonal 
antibodies might also be successfully bound to non–encapsulated 
effector siRNA duplex through the utilisation of an intermediate 
protamine molecule.38 This method was effective in silencing 
Hepatitis B Virus (HBV) gene expression, by adopting bespoke 
siRNA effectors linked to monoclonal antibodies targeting the 
hepatitis B surface antigen (HBsAg).38
Another efficient siRNA delivery method entails the 
linking of siRNA duplexes to target tissue specific aptamer 
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oligonucleotides to form siRNA – aptamer chimeras.39 A recent 
study applying such a targeted siRNA delivery system was that 
conducted by Zhou et al. which concerned the development of 
siRNAs in HIV-1 therapy.40 The study involved the attachment 
of siRNA duplexes having guide strands complementary to tat/
rev mRNA, linked to an aptamer which is specific for gp120, 
a characteristic envelope glycoprotein expressed by all HIV-1 
infected host cells.40 
The use of chitosan nanoparticles for the delivery of 
siRNAs safely to the target tissue is also being actively studied 
at present.41 Such nanoparticles, loaded with siRNAs directed 
against Tumour Necrosis Factor (TNF), have already shown 
to be successful in providing sustained knockdown of the TNF 
gene in murine arthritis models.41 However, all such therapies 
require repeated dosing as the siRNAs act on continually 
generated mRNA.
Conclusions
The concept of exploiting a generic pathway involved 
in controlling mammalian gene expression to dissect and 
comprehend purpose is undoubtedly alluring for all researchers 
in translational medicine and functional genomics. The 
advantage that any siRNA therapy offers is the specificity 
to target mRNA. Additionally, if the siRNA design is totally 
unique to the target mRNA designated for silencing, off - target 
effects can be minimised to negligible levels. The consequent 
discovery of such a pathway in the form of RNAi has now 
opened the doors for a new era of drug design, one which has 
the capacity to pinpoint the genes responsible for disease and 
consequently minimise their damaging effects on the individual 
patient. Furthermore, the possibility of severe adverse effect 
development is low, particularly if the siRNA therapy involves 
the use of a targeted delivery system which directs the siRNA 
effector molecule solely to the diseased tissue. 
Presently, we are only just starting to unravel the motives 
behind the existence of RNAi pathways. Undoubtedly, RNAi may 
be acclaimed as one of the most potent methods for mammalian 
gene regulation at the transcriptomic level, one which also 
blends in harmoniously with many other cellular and tissue 
pathways related to mammalian gene expression together with 
consequent proteomic and metabolomic processes. However, 
the field of RNAi therapeutics is very much in its early days, 
with intense research focusing on optimising a siRNA therapy 
with a delivery system that proves to be effective in silencing 
the target gene, with the added property of minimising the risk 
of siRNA – induced off - target effects. 
As the first decade of RNAi draws to a close, the next ten 
years commences with positive hope for the field of RNAi 
therapeutics. Focused research in siRNA design will help in 
developing siRNA duplexes with unique specificity for their 
target gene, thus rendering off target effects minimal. Advances 
in siRNA delivery systems will ensure that the siRNA will exert 
its gene silencing property at maximum efficiency only inside 
the target cells expressing disease-specific transcripts designated 
for knockdown. Optimisation of delivery systems might also 
prolong the duration of siRNA silencing effects, through the 
development of sustained release pharmaceutical formulations. 
In addition, the field of miRNA research bears with it a great 
potential for discovering hidden mechanisms by which non-
coding RNA sequences are being utilised for the scope of gene 
regulation, both in normal cellular processes and also in disease 
pathways, resulting in the identification of novel drug targets for 
future RNAi based therapeutics. Ultimately, the development of 
RNAi ‘magic bullets’ will respectively possess characteristics of 
unambiguous elimination of  disease-specific transcripts from 
specific cell types within the individual patient.
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